



**HAL**  
open science

## Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases

Ahmed Ghallab, Geraldine Celliere, Sebastian Henkel, Dominik Driesch, Stefan Hoehme, Ute Hofmann, Sebastian Zellmer, Patricio Godoy, Agapios Sachinidis, Meinolf Blaszkewicz, et al.

### ► To cite this version:

Ahmed Ghallab, Geraldine Celliere, Sebastian Henkel, Dominik Driesch, Stefan Hoehme, et al.. Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases. *Journal of Hepatology*, 2015, 64 (4), pp.860-871. 10.1016/j.jhep.2015.11.018 . hal-01257127

**HAL Id: hal-01257127**


**<https://hal.science/hal-01257127>**

Submitted on 18 Jan 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

### AUTHOR QUERY FORM

	<p><b>Journal: JHEPAT</b></p> <p><b>Article Number: 5901</b></p>	<p><b>Please e-mail your responses and any corrections to:</b></p> <p><b>E-mail: <a href="mailto:proofcorrections.esnl@elsevier.sps.co.in">proofcorrections.esnl@elsevier.sps.co.in</a></b></p>
---	--	---

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

Location in article	Query / Remark: <a href="#">click on the Q link to go</a> Please insert your reply or correction at the corresponding line in the proof
<u>Q1</u>	Your article is registered as a regular item and is being processed for inclusion in a regular issue of the journal. If this is NOT correct and your article belongs to a Special Issue/Collection please contact <a href="mailto:j.bakker@elsevier.com">j.bakker@elsevier.com</a> immediately prior to returning your corrections.
<u>Q2</u>	The author names have been tagged as given names and surnames (surnames are highlighted in teal color). Please confirm if they have been identified correctly.
<u>Q3</u>	The country name has been inserted for the affiliation '6'. Please check, and correct if necessary.
<u>Q4</u>	The affiliations '7' and '11' were identical, the latter has been removed, and hence the affiliation link the author 'Rolf Gebhardt' has been changed, accordingly. Please check, and correct if necessary.
<u>Q5</u>	One or more sponsor names may have been edited to a standard format that enables better searching and identification of your article. Please check and correct if necessary.
<u>Q6</u>	The country names of the Grant Sponsors are provided below. Please check and correct if necessary. 'BMBF' - 'Germany'.
<div style="border: 1px solid black; display: inline-block; padding: 5px;"> <p style="color: red; margin: 0;">Please check this box if you have no corrections to make to the PDF file</p> <div style="display: inline-block; width: 40px; height: 20px; border: 1px solid black; margin-left: 10px;"></div> </div>	


Thank you for your assistance.

Graphical abstract

Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases

pp xxx-xxx

Ahmed Ghallab\*, Géraldine Cellière, Sebastian G. Henkel, Dominik Driesch, Stefan Hoehme, Ute Hofmann, Sebastian Zellmer, Patricio Godoy, Agapios Sachinidis, Meinolf Blaszkewicz, Raymond Reif, Rosemarie Marchan, Lars Kuepfer, Dieter Häussinger, Dirk Drasdo, Rolf Gebhardt, Jan G. Hengstler\*



# Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases

Ahmed Ghallab<sup>1,2,\*</sup>, Géraldine Cellière<sup>3,†</sup>, Sebastian G. Henkel<sup>4,†</sup>, Dominik Driesch<sup>4</sup>, Stefan Hoehme<sup>5</sup>, Ute Hofmann<sup>6</sup>, Sebastian Zellmer<sup>7</sup>, Patricio Godoy<sup>1</sup>, Agapios Sachinidis<sup>8</sup>, Meinolf Blaszkewicz<sup>1</sup>, Raymond Reif<sup>1</sup>, Rosemarie Marchan<sup>1</sup>, Lars Kuepfer<sup>9</sup>, Dieter Häussinger<sup>10</sup>, Dirk Drasdo<sup>3,5,‡</sup>, Rolf Gebhardt<sup>7,‡</sup>, Jan G. Hengstler<sup>1,\*</sup>

<sup>1</sup>Leibniz Research Centre for Working Environment and Human Factors at the Technical University Dortmund, Dortmund, Germany; <sup>2</sup>Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt; <sup>3</sup>Institute National de Recherche en Informatique et en Automatique (INRIA), INRIA Paris-Rocquencourt & Sorbonne Universités UPMC Univ Paris 6, LJLL, France <sup>4</sup>BioControl Jena GmbH, Jena, Germany; <sup>5</sup>Interdisciplinary Centre for Bioinformatics, University of Leipzig, Leipzig, Germany; <sup>6</sup>Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Germany; <sup>7</sup>Institute of Biochemistry, Faculty of Medicine, University of Leipzig, Leipzig, Germany; <sup>8</sup>Institute of Neurophysiology and Center for Molecular Medicine (CMMC), University of Cologne, Robert-Koch-Str. 39, 50931 Cologne, Germany; <sup>9</sup>Computational Systems Biology, Bayer Technology Services GmbH, Leverkusen, Germany; <sup>10</sup>Clinic for Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University, Düsseldorf, Germany

**Background & Aims:** Recently, spatial-temporal/metabolic mathematical models have been established that allow the simulation of metabolic processes in tissues. We applied these models to decipher ammonia detoxification mechanisms in the liver. **Methods:** An integrated metabolic-spatial-temporal model was used to generate hypotheses of ammonia metabolism. Predicted mechanisms were validated using time-resolved analyses of nitrogen metabolism, activity analyses, immunostaining and gene expression after induction of liver damage in mice. Moreover, blood from the portal vein, liver vein and mixed venous blood was analyzed in a time dependent manner. **Results:** Modeling revealed an underestimation of ammonia consumption after liver damage when only the currently established mechanisms of ammonia detoxification were simulated. By iterative cycles of modeling and experiments, the reductive amidation of alpha-ketoglutarate ( $\alpha$ -KG) via glutamate dehydrogenase (GDH) was identified as the lacking component. GDH is released from damaged hepatocytes into the blood where it consumes ammonia to generate glutamate, thereby providing systemic pro-

tection against hyperammonemia. This mechanism was exploited therapeutically in a mouse model of hyperammonemia by injecting GDH together with optimized doses of cofactors. Intravenous injection of GDH (720 U/kg),  $\alpha$ -KG (280 mg/kg) and NADPH (180 mg/kg) reduced the elevated blood ammonia concentrations (>200  $\mu$ M) to levels close to normal within only 15 min.

**Conclusion:** If successfully translated to patients the GDH-based therapy might provide a less aggressive therapeutic alternative for patients with severe hyperammonemia.

© 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

## Introduction

Recent developments have strongly improved our capability to generate information at multiple spatial and temporal scales [1,2]. However, research on disease pathogenesis is hampered by the difficulty to understand the orchestration of individual components. Here, mathematical models help to formalize relations between components, simulate their interplay, and to study processes that are too complex to be understood intuitively [1]. This is particularly important when studying the pathophysiology of metabolic liver diseases, where due to zonation different metabolic processes take place in pericentral and periportal hepatocytes [3]. To be able to investigate such complex processes we recently established a technique of integrated metabolic spatial-temporal modeling (IM) [4]. These IM integrate conventional metabolic models into spatial-temporal models of the liver lobule [1,4,5]. The present study was motivated by the IM predictions, which proposed that the conventional mechanisms where ammonia is metabolized by urea cycle enzymes in the periportal compartments of the liver lobules and by glutamine synthetase (GS) reaction in the pericentral compartments (Supplementary

Keywords: Systems biology; Spatio-temporal model; Ammonia; Liver damage; Liver regeneration.

Received 23 March 2015; received in revised form 15 November 2015; accepted 16 November 2015

\* Corresponding authors. Addresses: Leibniz Research Centre for Working Environment and Human Factors, IfADO – Ardeystr. 67, D-44139 Dortmund, Germany. Tel.: +49 02311084 356; fax: +49 02311084 403 (A. Ghallab) or Leibniz Research Centre for Working Environment and Human Factors, IfADO – Ardeystr. 67, D-44139 Dortmund, Germany. Tel.: +49 02311084 349; fax: +49 02311084 403 (J.G. Hengstler).

E-mail addresses: ghallab@ifado.de (A. Ghallab), hengstler@ifado.de (J.G. Hengstler).

<sup>†</sup> These authors contributed equally to the work.

<sup>‡</sup> These authors share co-senior authorship.

Abbreviations: CCl<sub>4</sub>, carbon tetrachloride; GDH, glutamate dehydrogenase; AOA, aminoxy acetate; ALT, alanine transaminase; AST, aspartate transaminase;  $\alpha$ -KG, alpha-ketoglutarate; PDAC, 2,6-pyridinedicarboxylic acid.



ELSEVIER

## Research Article

Fig. 1) failed to explain the experimental findings [4]. The IM was applied to an experimental scenario, where the entire pericentral and a part of the periportal compartment of the liver lobules were destroyed by a single high dose of the hepatotoxic compound carbon tetrachloride (CCl<sub>4</sub>). This leads to compromised nitrogen metabolism and hyperammonemia. In the present study, we performed a series of new experiments accompanied by simulations with novel models to explore the mechanism responsible for the observed discrepancy. Experimentally, the time-resolved analysis of metabolites and metabolic activities after CCl<sub>4</sub> intoxication offers good conditions to study ammonia detoxification and possible compensatory mechanisms during the damage and regeneration process. Time-resolved analysis of metabolites was performed in the portal vein and heart blood, representing the 'liver inflow', and in the liver vein as 'liver outflow'. These analyses allowed a precise experimental validation of model predictions. Finally, iterative cycles of modeling and experimental validation allowed the identification of a so far unrecognized mechanism of ammonia detoxification. Importantly, this mechanism could be exploited therapeutically to reduce elevated blood ammonia concentrations close to normal levels by intravenous injection of glutamate dehydrogenase (GDH; 720 U/kg) and its cofactors alpha-ketoglutarate ( $\alpha$ -KG; 280 mg/kg) as well as NADPH (180 mg/kg). This example illustrates how concrete therapies can be derived by model guided experimental strategies.

### Materials and methods

A detailed description of materials and methods is provided in the [Supplementary materials](#). Male C57BL/6N 10–12 weeks old mice were used (Charles River, Sulzfeld, Germany). Acute liver damage was induced by intraperitoneal injection of 1.6 g/kg CCl<sub>4</sub>, unless other doses are indicated. Blood was taken from mice under anesthesia from the portal and hepatic veins, as well as the right heart chamber, and plasma was separated. Liver tissue samples were collected from defined anatomical positions for histopathology, immunohistochemistry, enzyme activity assays, gene array and q-RT-PCR analyses. The dead cell area was quantified in hematoxylin and eosin stained tissue sections using Cell^M software (Olympus, Hamburg, Germany). Whole-genome analysis of gene expression in mouse liver tissue was performed in control as well as after CCl<sub>4</sub> intoxication with Affymetrix gene arrays. The latter techniques are described fully in the [Supplementary materials and methods](#). The analysis of ammonia and further metabolites was performed using commercially available kits. Concentrations of amino acids and organic acids in liver tissue were measured in duplicate using GC-MS. GS, GDH and transaminases activity assays were performed photometrically as described in the [Supplementary materials and methods](#). NADP<sup>+</sup> and NADPH were analyzed by LC-MS. Mouse hepatocytes were isolated by a two-step EGTA/collagenase perfusion technique and either used directly in suspension or cultivated in collagen sandwiches ([Supplementary materials and methods](#)). For the mathematical modeling of ammonia and the related metabolites the integrated metabolic, spatio-temporal model was applied [4,5]. In addition, the IM was replaced by a set of novel models that include further reactions and the blood compartment of the liver ([Supplementary materials and methods](#)). Statistical analysis was done with SPSS software as described in the [Supplementary materials](#).

### Results

*An integrated spatial-temporal-metabolic model suggests a so far unrecognized mechanism of ammonia detoxification*

The detoxification process in healthy, damaged and regenerating livers was simulated using a recently established integrated metabolic IM [4]. To compare the simulated metabolite concen-

trations with the *in vivo* situation, an experiment was performed in which blood was collected from the portal vein (representing 85% of the 'liver inflow'), the heart (representing 15% of the 'liver inflow'), and the hepatic vein (representing the 'liver outflow') in a time-resolved manner after CCl<sub>4</sub> injection (Fig. 1A; [Supplementary Fig. 2](#)). The result shows that ammonia is detoxified during its passage through the liver as illustrated by the difference in ammonia concentrations between the portal vein and the hepatic vein in the control mice (Fig. 1B). This detoxification process is compromised after liver damage, particularly on days 1 and 2. Surprisingly, the IM model predicted higher ammonia concentrations than those experimentally observed, particularly on day 1 (Fig. 1C; see the [video in the Supplementary data](#)). Analyses of heart blood demonstrate the contribution of the extrahepatic compartment, which includes brain, muscles, kidneys and blood, to ammonia detoxification between days 1 and 4 after the induction of liver damage. However, this extrahepatic contribution is small compared to detoxification by the liver ([Supplementary Figs. 2–8](#)). In addition to the time-resolved study, similar experiments were also performed in a dose dependent manner on day 1 after CCl<sub>4</sub> administration when the discrepancy between simulated and measured ammonia was maximal. For this purpose, doses ranging between 10.9 and 1600 mg/kg CCl<sub>4</sub> were tested, resulting in a concentration dependent increase in the dead cell area, with only the highest dose causing damage to the entire CYP2E1 positive pericentral region of the liver lobule (Fig. 1D; [Supplementary Fig. 9A, B](#)). Destruction of the GS positive area occurred in with doses ranging between 38.1 and 132.4 mg/kg (Fig. 1D, E; [Supplementary Fig. 9C](#)); also *CPS1* showed a dose dependent decrease ([Supplementary Fig. 9C](#)) leading to compromised ammonia metabolism ([Supplementary Fig. 10](#)). Using the IM [4], we also observed a discrepancy between the predicted and measured ammonia in the dose dependent study (Fig. 1F).


To find an explanation for this discrepancy, we performed time-resolved gene array analysis of mouse liver tissue after CCl<sub>4</sub> intoxication (Fig. 2A). Fuzzy clustering identified seven gene clusters which reflected time dependent gene expression alterations [6]. Clusters 4 and 6 contained genes whose expression was transiently repressed at early time points after CCl<sub>4</sub> intoxication (Fig. 2B). Further bioinformatics analyses revealed an over representation of nitrogen/ammonia metabolism KEGG and Gene ontology terms of genes in cluster 4 (Fig. 2C, D). Genes relevant for ammonia metabolism were further studied by qRT-PCR, immunostaining and activity assays. GS is the key enzyme for ammonia detoxification in the pericentral compartment. RNA levels of GS started to decrease as early as 6 h after CCl<sub>4</sub> injection, it was at its lowest between days 1 and 4, before finally recovering to initial levels between days 6 and 30 (Fig. 2E). A similar time-dependent curve was obtained for GS activity although the decrease occurred slightly later than that of RNA with very low levels between days 2 and 4 (Fig. 2E). The pattern and intensity of GS immunostaining was found to be comparable to GS activity (Fig. 2F). In addition, ornithine aminotransferase (OAT), an enzyme exclusively localized in GS positive pericentral hepatocytes that provides additional glutamate for fixing ammonia [7], decreased to almost undetectable levels with a delayed recovery ([Supplementary Fig. 3A](#)). The key enzymes of the periportal compartment, *CPS1*, *ASS1*, *ASL* and *arginase1* were similarly analyzed in the same tissue ([Supplementary Figs. 3B and 4](#)). Extending the IM [4], with time-dependent



193 enzyme concentrations (model 1), did not remove the discrepancy  
 194 between model predictions and experimental data  
 195 (Supplementary Fig. 11), indicating that our model lacks a relevant,  
 196 but so far unrecognized mechanism of ammonia detoxification.  
 197

Acute liver damage provides systemic protection against ammonia 198  
 by GDH release 199

Further evidence that an unrecognized mechanism of ammonia 200  
 detoxification exists arose from metabolic analyses performed 201



Liver Failure and Growth

## Research Article

using plasma from mice after CCl<sub>4</sub> injection (Fig. 3A). Most of the analyzed factors in plasma (urea, glutamine, glucose, lactate, pyruvate, alanine, arginine and other amino acids: Supplementary Figs. 4–6) were within the expected concentration ranges,  $\alpha$ -KG, which dramatically decreased between 12 h and day 2 (Fig. 3A). This decrease was accompanied by an almost concurrent increase in glutamate levels, which persisted longer than the drop in  $\alpha$ -KG. One potential explanation is the delayed recovery of GS, which uses glutamate and ammonia to form glutamine (Fig. 2E, F). The decrease in  $\alpha$ -KG (and the increase in glutamate) was also accompanied by increased GDH activity in plasma, because GDH is released from damaged hepatocytes (Fig. 3A). The present observations suggest that GDH released from the damaged hepatocytes into the blood catalyzes, at least transiently, a reaction that consumes ammonia to produce glutamate (Fig. 3D). To test this hypothesis, we collected plasma from mice on day 1 after CCl<sub>4</sub> injection. Addition of  $\alpha$ -KG alone was sufficient to slightly but significantly decrease blood ammonia concentrations (Fig. 3B). This decrease was enhanced by further adding NADPH and particularly GDH; whereas the GDH inhibitor, PDAC completely antagonized the effect. To test also higher ammonia concentrations typically observed in patients with severe pre-coma hyperammonemia, 600  $\mu$ M ammonia was added to plasma collected on day 1 after CCl<sub>4</sub> administration. Under these conditions,  $\alpha$ -KG also reduced ammonia and increased glutamate concentrations (Fig. 3C; Supplementary Fig. 12A). Together, these experiments suggest that a GDH reaction consuming ammonia in blood takes place when GDH is released from acutely damaged livers (Fig. 3D).

### Validation of the 'GDH-driven ammonia consumption' in hepatocytes

The experiments described above suggest that high ammonia concentrations in plasma leads to a 'reverse' GDH reaction, which consumes rather than produces ammonia. To test whether this 'GDH-driven ammonia consumption' occurs not only in plasma but also in cells, we used an *in vitro* system with primary mouse hepatocytes incubated with ammonia in suspension (Fig. 4). PDAC was used to inhibit GDH (Fig. 4A) in order to determine its influence on ammonia metabolism. In hepatocytes isolated from control mice, unphysiologically high ammonia concentrations (2 mM) were required until PDAC caused a significant increase of ammonia levels in the suspension buffer (Fig. 4B). However, when hepatocytes from mice 24 h after CCl<sub>4</sub> intoxication were used, PDAC treatment increased ammonia concentrations in the suspension buffer, even with 0.5 mM ammonia. Furthermore, in the absence of ammonia, hepatocytes secreted a small but statistically significant amount of ammonia into the buffer. Similarly, glutamate production was reduced by PDAC,


an effect that was also stronger in hepatocytes isolated from CCl<sub>4</sub>-exposed mice (Fig. 4C), which corresponds to the reverse GDH reaction proposed in Fig. 3D (right panel). CCl<sub>4</sub> destroys the pericentral hepatocytes (Fig. 1D), which explains the reduced glutamine generation by GS (Fig. 4D) and compromises urea cycle enzymes (Supplementary Fig. 3B, C), which explains the reduced urea production (Fig. 4E). Similar experiments were also performed with cultivated (instead of suspended) hepatocytes from untreated mice. The results demonstrate that inhibition of GDH at high ammonia concentrations increases ammonia-induced cytotoxicity (Supplementary Fig. 12B). These results show that the catalytic direction of GDH reverses a clearly becomes ammonia consuming also in hepatocytes in order to compensate the compromised metabolism by urea cycle enzymes and GS after intoxication.

Further evidence emerges from simulations with a set of novel models 1–4 (Supplementary Fig. 11). If a reversible GDH reaction was integrated into the hepatocyte compartment (Fig. 5A; Supplementary Fig. 11), the discrepancy between *in vivo* measured and simulated ammonia concentrations (Fig. 1C) completely disappeared (Fig. 5B). The quantitative agreement was obtained even without considering the blood compartment of the liver, suggesting that after CCl<sub>4</sub>-induced damage, the ammonia consumption catalyzed by GDH in the hepatocytes represents the missing ammonia sink predicted by [4].

### Therapy of hyperammonemia based on the reverse GDH reaction

The above described ammonia consumption catalyzed by the GDH reaction (Figs. 3B–D and 4) and the aforementioned decrease in plasma  $\alpha$ -KG levels (Fig. 3A) prompted us to test whether supplementation of  $\alpha$ -KG in mice helps to detoxify ammonia. Therefore, mice received a hepatotoxic dose of CCl<sub>4</sub> (1.6 g/kg) and 24 h later  $\alpha$ -KG (280 mg/kg) was injected into the tail vein. Blood was collected immediately before as well as 15, 30 and 60 min after injection of  $\alpha$ -KG. A decrease in plasma ammonia concentrations by 31, 40 and 43% was observed 15, 30 and 60 min after  $\alpha$ -KG injection, respectively (Fig. 6A). Glutamate increased after 15 min and decreased again after longer periods probably due to the consumption by further metabolism.  $\alpha$ -KG transiently increased in plasma after injection and then rapidly decreased. Analysis of GDH activity demonstrated that the experiment was performed under conditions of high plasma activity. In control mice, injection of  $\alpha$ -KG did not alter blood concentrations of ammonia or glutamate (Fig. 6B). In addition, plasma  $\alpha$ -KG levels were lower in CCl<sub>4</sub>-treated mice compared to the control mice, suggesting increased consumption in mice with damaged livers.


**Fig. 1. Evidence for a so far unrecognized mechanism of ammonia detoxification.** (A) Experimental design. (B) Ammonia concentrations in the portal vein, hepatic vein and heart. \**p* < 0.05 compared to the corresponding controls (0 h). (C) Integrated metabolic spatio-temporal model using the technique described by [4] (video in the Supplementary data). Predicted ammonia concentrations in the liver outflow are higher compared to the experimental data. \*\*\**p* < 0.001, \*\**p* < 0.01 and \**p* < 0.05 compared to the measured ammonia output. (D) Dose dependent experiment (10.9 to 1600 mg/kg CCl<sub>4</sub> 24 h after administration) showing macroscopic alterations with a spotted pattern at 132.4 mg/kg and higher doses, corresponding to the central necrotic lesion in hematoxylin/eosin staining, scale bars: 100  $\mu$ m. Destruction of the pericentral CYP2E1 positive region which begins at 132.4 mg/kg with central necrosis still surrounded by CYP2E1 positive surviving hepatocytes; the entire CYP2E1 positive region was destroyed at the highest dose of 1600 mg/kg. The GS positive region was destroyed only at 132.4 mg/kg and higher doses, which corresponds to the decrease in GS activity (E), scale bars: 200  $\mu$ m. \**p* < 0.05 when compared to the control group (0). (F) Comparison of analyzed and simulated ammonia concentrations in the liver vein for the experiment in (D); meas. in: analyzed concentrations in the portal vein (representing 85% of the liver inflow) and heart blood (representing 15% of the liver inflow); meas. out: analyzed concentrations in the liver vein; sim. out: simulated concentrations in the liver vein. Data are mean values and SD of three mice per time point and dose of CCl<sub>4</sub>. \*\*\**p* < 0.001 and \*\**p* < 0.01 compared to the measured ammonia output.




**Fig. 2. Spatio-temporal alterations of ammonia metabolizing enzymes after CCl<sub>4</sub> intoxication.** (A) Experimental design. (B) Time dependent changes of gene expression in fuzzy cluster 4 from [6]. The dots correspond to the average of the mean scaled values for all 310 genes, between their respective maximal and minimal expression levels at each time point, using healthy liver (time 0) as reference. Error bars indicate standard error. (C) Changes in expression of genes associated to the KEGG terms ammonia/nitrogen metabolism (Gene Ontology [GO] ID 910) as revealed by KEGG pathways enrichment analysis in fuzzy cluster 4 ( $p = 2.36 \times 10^{-7}$ ). (D) Changes in the expression of genes associated to the GO terms 'urea cycle/urea metabolic process' (Gene Ontology ID 0000050 and 0019627 respectively) as revealed by GO enrichment analysis in fuzzy cluster 4 ( $p = 3.83 \times 10^{-4}$ ). In C and D, the values indicate fold of expression over healthy liver at each time point after CCl<sub>4</sub> administration, and correspond to the average of 5 independent biological replicates. Time course of GS RNA levels, GS activity (E) and immunostaining (F), Scale bars: 200  $\mu$ m. \* $p < 0.05$  when compared to the control group (0 h).



Research Article




**Fig. 3. Detoxification of ammonia by a reverse GDH reaction.** (A) After induction of liver damage by CCl<sub>4</sub>, plasma activity of GDH transiently increases. This is accompanied by a decrease in alpha-ketoglutarate (α-KG) and an increase in glutamate. \**p* < 0.05 when compared to the corresponding control (0 h). Similar results were observed in liver tissue (Supplementary Tables 1 and 2). (B) Validation of the reverse GDH reaction using an inhibitor of GDH (PDAC). Plasma of mice 24 h after CCl<sub>4</sub> injection was analyzed. α-KG was added alone or in combination with AOA, NADPH, GDH and PDAC. \*\*\**p* < 0.001, \*\**p* < 0.01 and \**p* < 0.05 when compared to controls (0). (C) A similar experimental design was chosen as in B. However, 600 µM ammonia was added to also test the reaction at a higher but still clinically relevant concentration. α-KG decreases ammonia and increases glutamate concentrations, which can be blocked by the GDH inhibitor, PDAC. \*\*\**p* < 0.001, \*\**p* < 0.01 and \**p* < 0.05 when compared to the NH<sub>4</sub>Cl group (0 h). Data are mean values and SD of 3 biological replicas. (D) Concept of the reverse glutamate dehydrogenase (GDH) reaction. In normal periportal hepatocytes, GDH generates ammonia, which is detoxified by the urea cycle. In pericentral hepatocytes, GDH generates glutamate which is required as a substrate for the GS reaction to form glutamine (Gln). Biosynthesis of α-KG takes place in the periportal hepatocytes; α-KG is then partially exported and taken up again by the pericentral hepatocytes, where it is needed for GS [25,26]. After induction of liver damage, the expression of urea cycle enzymes decreased and the pericentral region with GS is completely destroyed. This leads to increased blood ammonia concentrations. However, also GDH is released from damaged hepatocytes and catalyzes a reaction in blood consuming ammonia and α-KG to generate glutamate (Glu). This reaction can go until α-KG in blood is consumed. In this situation α-KG and NADPH should be therapeutically substituted.



**Fig. 4. Ammonia consumption by GDH in primary mouse hepatocytes.** Hepatocytes were isolated from  $\text{CCl}_4$  (1.6 g/kg) intoxicated (day 1) and untreated mice and suspended at a concentration of 2 million hepatocytes/ml for 1 h with different concentrations of ammonia. (A) Inhibition of GDH activity by PDAC. (B) Compromised ammonia detoxification after GDH inhibition. (C) Reduced glutamate production by GDH inhibition. \*\*\* $p < 0.001$ , \*\* $p < 0.01$  and \* $p < 0.05$  compared to - PDAC. ° $p < 0.01$  and ° $p < 0.05$  compared to hepatocytes from untreated mice. (D & E) compromised urea and glutamine production by hepatocytes of  $\text{CCl}_4$  intoxicated mice. \*\* $p < 0.01$  and \* $p < 0.05$  compared to hepatocytes from untreated mice. Data are mean values and SD of three independent experiments.

In the aforementioned experiment, the molar amount of glutamate produced in the damaged liver after  $\alpha$ -KG injection was higher than ammonia consumption (Fig. 6A). Therefore, the results cannot only be explained by the reverse GDH reaction, but may be due to the consumption of  $\alpha$ -KG by transaminases that contribute to the generation of glutamate. Indeed, tail vein injection of the transaminases inhibitor AOA prior to  $\alpha$ -KG injection reduced the production of glutamate (Fig. 6C) and improved ammonia detoxification. The efficiency of transaminases inhibition by AOA *in vivo* has been confirmed in preliminary experiments (Supplementary Figs. 13 and 14).

The reverse GDH reaction requires NADPH as a cofactor; however, NADPH concentrations are very low in blood. To determine how NADPH levels are altered in our model of liver damage, both NADPH and its oxidized form  $\text{NADP}^+$  were analyzed. Blood con-




**Fig. 5. Integration of the GDH reaction into the metabolic model.** (A) Scheme of the metabolic reactions and zones of the extended model including GDH in the blood of the liver and hepatocytes. (B) The model extension leads to a better fit between simulated and experimental data.

centrations of both NADPH and  $\text{NADP}^+$  increased after induction of liver damage by  $\text{CCl}_4$  (Supplementary Fig. 15A). In addition, an enhanced  $\text{NADP}^+/\text{NADPH}$  ratio was observed in both blood and liver tissue (Supplementary Fig. 15B). This increase in  $\text{NADP}^+/\text{NADPH}$  ratio fits to a switch in the GDH reaction from NADPH generation to NADPH consumption. Despite the increase in NADPH after induction of liver damage, the concentrations are still relatively low. Therefore, to study the influence of NADPH, plasma from mice collected 24 h after  $\text{CCl}_4$  injection was incubated with varying concentrations of NADPH in the presence of  $\text{NH}_4\text{Cl}$  (1 mM),  $\alpha$ -KG (3 mM), AOA (1 mM) and GDH (12,000 U/l) for one hour. A concentration dependent decrease in plasma ammonia and an increase in glutamate were observed with increasing concentrations of NADPH (Fig. 7A). A similar trend for ammonia and glutamate was observed with increasing concentrations of  $\alpha$ -KG and GDH (Fig. 7B, C). Moreover, addition of AOA reduced both ammonia and glutamate concentrations (Supplementary Fig. 16). To understand how the orientation of the GDH reaction is controlled by ammonia and glutamate concentrations, titration experiments were performed, which indicated that GDH significantly consumes ammonia beginning at concentrations of 150  $\mu\text{M}$  and higher (Fig. 7D). In contrast, unphysiologically high concentrations of more than 10 mM glutamate were required to block the reaction (Fig. 7E).

Based on these *in vitro* optimized concentrations, we designed an *in vivo* study to treat hyperammonemia in mice. After the induction of liver damage by  $\text{CCl}_4$ , transaminases activities were inhibited by AOA (13 mg/kg; tail vein injection; 24 h after  $\text{CCl}_4$  administration). Thirty minutes later a cocktail of  $\alpha$ -KG (280 mg/kg), GDH (720 U/kg) and NADPH (180 mg/kg) was intravenously injected. A dose of 280 mg/kg  $\alpha$ -KG was chosen because

## Research Article



**Fig. 6. Reduction of blood ammonia concentrations by  $\alpha$ -KG.** (A) Tail vein injection of 280 mg/kg  $\alpha$ -KG into mice 24 h after induction of liver damage by  $\text{CCl}_4$  (1.6 g/kg). (B) Control experiment with  $\alpha$ -KG (280 mg/kg) injected into the tail vein of untreated mice. \*\*\* $p < 0.001$ , \*\* $p < 0.01$  and \* $p < 0.05$  when compared to the control group (0). (C) Influence of the transaminase inhibitor, AOA (13 mg/kg; tail vein injection) on ammonia detoxification by  $\alpha$ -KG. \*\* $p < 0.01$  and \* $p < 0.05$  when compared to the corresponding control. Data are mean values and SD of three mice treated at different experimental days with individually prepared  $\alpha$ -KG.

342 it transiently normalized  $\alpha$ -KG levels in mice 24 h after  $\text{CCl}_4$ .  
 343 720 U/kg GDH was used because it resulted in plasma levels of  
 344 approximately 6000 U/l 15 min after injection (Supplementary  
 345 Fig. 17), an activity level shown to allow maximal ammonia  
 346 consumption in plasma *in vitro* (Fig. 7C). The dose of 180 mg/kg  
 347 NADPH was also considered as adequate in a pharmacokinetic  
 348 experiment (Supplementary Fig. 18) as it transiently increased  
 349 plasma NADPH to approximately 1.6 mM 2 min after injection.  
 350 Injection of the  $\alpha$ -KG/GDH/NADPH cocktail (KGN cocktail)  
 351 reduced ammonia concentrations from 213 to 74  $\mu\text{M}$  within  
 352 15 min after administration (Fig. 8). Simultaneously, glutamate  
 353 levels increased from 131 to 369  $\mu\text{M}$ . Analysis of  $\alpha$ -KG and  
 354 GDH activity in the plasma showed that substitution was success-  
 355 ful 15 min after the injection of the KGN cocktail. Moreover,  
 356 the activities of aspartate and alanine aminotransferase were suc-  
 357 cessfully inhibited by AOA. The mice were observed for three  
 358 weeks after the experiment and did not show any complications.


## 359 Discussion

360 Guided by simulations with an IM predicting a missing ammonia  
 361 sink after severe  $\text{CCl}_4$ -induced liver damage, we identified the  
 362 GDH reaction as fundamental for ammonia consumption, which

363 can be used therapeutically by the administration of a cocktail  
 364 of GDH and cofactors.

365 Therapy for hyperammonemia remains challenging [8–10].  
 366 Hemodialysis is the most efficient treatment for reducing ele-  
 367 vated blood ammonia concentrations [11,12]. For milder forms  
 368 of hyperammonemia, pharmacologic management is possible  
 369 [13]. Efficient strategies for patients with urea cycle defects  
 370 include infusion of phenylacetate or benzoate. Phenylacetate  
 371 combines with glutamine to form a product which can be  
 372 excreted by the kidneys [9,13,14]. Conversely, benzoate combines  
 373 with glycine to form hippurate, which is also excreted in urine  
 374 [13,15]. Both compounds reduce the total body nitrogen content;  
 375 however, this therapy has also failed in a fraction of patients with  
 376 hyperammonemic crisis who became refractory most probably  
 377 due to the accumulation of nitrogen waste [9]. This led to the  
 378 concept that only blood ammonia concentrations below 500  $\mu\text{M}$   
 379 should be treated pharmacologically; whereas, more severe  
 380 hyperammonemia requires aggressive interventions with renal  
 381 replacement therapies, such as hemodialysis [12,16]. In such sit-  
 382 uations with either severe or refractory hyperammonemia the  
 383 therapeutic strategy developed in the present study may be an  
 384 alternative to hemodialysis.

385 The current experiments demonstrate that infusion of a KGN-  
 386 cocktail reduces ammonia close to normal levels within minutes.




**Fig. 7. Optimization of cofactor concentrations for the GDH reaction and identification of maximal GDH activity.** (A) NADPH: mouse plasma collected 24 h after CCl<sub>4</sub> injection was incubated with varying concentrations of NADPH in the presence of NH<sub>4</sub>Cl (1 mM) and other cofactors; aminooxy acetate (AOA) (1 mM), α-KG (3 mM) and GDH (12,000 U/L) for one hour. (B) Alpha-ketoglutarate (α-KG): plasma was collected from mice on day one after CCl<sub>4</sub> administration and incubated with varying concentrations of α-KG in the presence of NH<sub>4</sub>Cl (1 mM) and other cofactors; AOA (1 mM), NADPH (1 mM) and GDH (12,000 U/L). (C) GDH: plasma from mice collected 24 h after CCl<sub>4</sub> injection was incubated with varying concentrations of GDH in the presence of NH<sub>4</sub>Cl (1 mM) and other cofactors; AOA (1 mM), α-KG (3 mM), and NADPH (1 mM) for one hour. \*\*\**p* < 0.001, \*\**p* < 0.01 and \**p* < 0.05 compared to the situation where the plasma was incubated with only NH<sub>4</sub>Cl. (D) Ammonia detoxification by the cocktail. Different ammonia concentrations were added to plasma of untreated mice and a cocktail of α-KG (3 mM), NADPH (0.5 mM), GDH (6000 U/L) and AOA (1 mM) was added to analyze ammonia and glutamate one hour later. \*\*\**p* < 0.001, \*\**p* < 0.01 and \**p* < 0.05 compared – cocktail. (E) Ammonia (600 μM) detoxification by the cocktail was only blocked by unphysiologically high glutamate concentrations. \*\*\**p* < 0.001 compared to NH<sub>4</sub>Cl alone. Data are mean values and SD of three biological replicates.

387 Under these conditions, a GDH-catalyzed reaction takes place in  
 388 blood where ammonia and α-KG are consumed to form glutamate  
 389 in an NADPH-dependent reaction. GDH was also previously  
 390 reported to switch its catalytic orientation under physiological  
 391 conditions. In the periportal compartment of the liver lobule,  
 392 GDH generates ammonia (Fig. 3D), which fuels the urea cycle.  
 393 In the pericentral compartment, GDH is known to consume  
 394 ammonia to generate glutamate for the GS reaction [17–19].

The present study shows by use of a GDH inhibitor that GDH  
 released from damaged liver tissue may catalyze an ammonia  
 consuming reaction under conditions of hyperammonemia. By  
 releasing GDH from damaged hepatocytes into the blood, the  
 damaged liver provides a mechanism that reduces blood ammonia  
 levels. However, this protective mechanism is limited by the  
 availability of the GDH substrate, α-KG. The present study shows  
 that α-KG strongly decreases upon induction of acute liver dam-



## Research Article



**Fig. 8. Treatment of hyperammonemia by injection of a cocktail of GDH and optimized cofactor doses.** A cocktail of GDH (720 U/kg),  $\alpha$ -KG (280 mg/kg) and NADPH (180 mg/kg) (KGN) was injected into mice 24 h after induction of liver damage using  $\text{CCl}_4$  (1.6 g/kg). Thirty minutes prior to treatment with the cocktail, mice received a single dose of 13 mg/kg AOA to block transaminases. Injection of the KGN cocktail reduced ammonia and increased glutamate concentrations in the blood of mice.  $\alpha$ -KG and GDH activity increased while aspartate (AST) and alanine aminotransferase (ALT) activities decreased. Data are mean values and SD of four mice treated at different experimental days with individually prepared therapeutic cocktails. \*\*\* $p < 0.001$ , \*\* $p < 0.01$  and \* $p < 0.05$  when compared to the control group (-30).

age, because it is consumed by the reverse GDH reaction. This prompted us to supplement  $\alpha$ -KG, increase blood concentrations of NADPH, and infuse GDH. Indeed, the combined injection of  $\alpha$ -KG, GDH and NADPH efficiently reduced blood ammonia concentrations. A GDH bolus was injected to result in plasma peak concentrations between 5000 and 6000 U/L. This is in the same order of magnitude as observed in patients after acetaminophen intoxication [20]. Therefore, in patients with acute liver intoxication with high blood GDH, therapy with  $\alpha$ -KG and NADPH might be sufficient. However, it should be considered that the GDH reaction in blood described here (Fig. 3D) does not explain all experimental observations:  $\alpha$ -KG decreases significantly 12 h after  $\text{CCl}_4$  administration when there is no significant increase in blood GDH (Fig. 3A). This discrepancy may be explained by the intracellular change of the catalytic direction of GDH in the periportal hepatocytes, which may precede the GDH release into the blood. However, this was not further analyzed in the present study as

we choose to focus on the therapeutically more relevant GDH reaction taking place in blood.

$\alpha$ -KG was previously tested for the treatment of hyperammonemia between 1964 and 1978 [21,22], but this strategy was abandoned because it was not sufficiently efficient for clinical application. The reverse GDH reaction in the blood and its requirement for NADPH as a cofactor was not yet known when the early therapeutic studies with  $\alpha$ -KG were performed. In addition, injection of  $\alpha$ -KG alone in the present study resulted in only a relatively weak reduction of hyperammonemia. This reduction may be possible because in addition to GDH, NADPH is also released from deteriorating hepatocytes after  $\text{CCl}_4$  injection.

The concept of treating hyperammonemia by  $\alpha$ -KG/GDH/NADPH infusion originates from simulations using an integrated metabolic spatio-temporal model [4]. This model is based on well-understood pathways of ammonia detoxification, such as urea cycle enzymes and the GS reaction [23,24]. It predicted higher ammonia concentrations compared to the measured data. Therefore, we analyzed liver tissue during the damage induction and regeneration processes, but the results could also not explain the discrepancy. Time-resolved gene array experiments following  $\text{CCl}_4$  injection led to the observation that a general decrease in metabolizing enzymes occurs including enzymes involved in ammonia metabolism. All enzymes of the urea cycle were transcriptionally downregulated by at least 60%. Factors identified by the gene array analysis were further analyzed by activity assays and immunostaining. Key observations were: (a) the GS positive region, which is initially completely destroyed by  $\text{CCl}_4$ , shows a delayed recovery and does not return to normal levels before day 12; and (b) CPS1, the rate limiting enzyme in the urea cycle normally expressed in the periportal region, is downregulated during the destruction process (days 1-3), but its expression then extends throughout the entire liver lobule during days 4-6. The other urea cycle enzymes showed a similar time course as CPS1 with the exception of arginase1, which decreased only slightly during the destruction and regeneration process. Glutaminase showed a similar time course and pattern as CPS1. Nevertheless, none of these alterations could explain the observed discrepancy. However, the refined models that take into account the reversible GDH reaction show an excellent agreement with the experimental data suggesting that consumption by the GDH reaction represents the previously predicted ammonia sink, hence providing an example for model guided experimentation.

In conclusion, a novel form of therapy has been identified that allows the rapid correction of hyperammonemia by the infusion of  $\alpha$ -KG, GDH and NADPH. This pharmacotherapy may prove relevant as an emergency therapy for episodes of hyperammonemia in urea cycle disease or liver cirrhosis.

#### Financial support

This study was supported by the BMBF funded projects Virtual Liver (FKZ0315739), Lebersimulator and FP 7EU NOTOX.

#### Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

476	<b>Authors' contributions</b>		
478	Ahmed Ghallab: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; statistical analysis; critical revision of the manuscript.		
479			
480	Sebastian G. Henkel: mathematical modeling (integrated model of Schliess <i>et al.</i> (2014), model 0 and extrahepatic mass balance); analysis and interpretation of data; drafting of the manuscript		
481			
482	Géraldine Cellière: mathematical modeling (novel ammonia detoxification models, extension of model 0); analysis and interpretation of data; drafting of the manuscript, statistical analysis.		
483			
484	Dominik Driesch: mathematical modeling (integrated model of Schliess <i>et al.</i> (2014), model 0 and extrahepatic mass balance); analysis and interpretation of data; drafting of the manuscript.		
485			
486	Stefan Hoehme: mathematical modeling (integrated model of Schliess <i>et al.</i> (2014), model 0); analysis and interpretation of data; drafting of the manuscript.		
487			
488	Ute Hofmann: acquisition of data; analysis and interpretation of data; technical support; drafting of the manuscript.		
489			
490	Sebastian Zellmer: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript.		
491			
492	Patricio Godoy: acquisition of data; analysis and interpretation of data; drafting of the manuscript.		
493			
494	Agapios Sachinidis: acquisition of data; analysis and interpretation of data; drafting of the manuscript.		
495			
496	Meinolf Blaszkewicz: acquisition of data; analysis and interpretation of data; technical support; drafting of the manuscript.		
497			
498	Raymond Reif: analysis and interpretation of data; drafting of the manuscript.		
499			
500	Rosemarie Marchan: critical revision of the manuscript.		
501			
502	Lars Kuepfer: mathematical modeling; drafting of the manuscript.		
503			
504	Dieter Häussinger: study concept and design; critical revision of the manuscript.		
505			
506	Dirk Drasdo: study concept and design; mathematical modeling (integrated model of Schliess <i>et al.</i> (2014), model 0 and novel models); analysis and interpretation of data; drafting of the manuscript, statistical analysis, critical revision of the manuscript		
507			
508	Rolf Gebhardt: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript, critical revision of the manuscript.		
509			
510	Jan G. Hengstler: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript, statistical analysis, critical revision of the manuscript; study supervision.		
511			
512			
513			
514			
515			
516			
517			
518			
519			
520			
521			
522			
523			
524			
525			
526			
527			
528			
529	<b>Acknowledgments</b>		
530	We thank Mrs. Gabi Baumhoer, Mrs. Georgia Günther and Mrs. Brigitte Begher-Tibbe – Leibniz Research Centre for Working Environment and Human Factors at the Technical University Dortmund, Dortmund, Germany; and Ms. Margit Henry and Ms. Tamara Rotshteyn – Institute of Neurophysiology and Center		
531			
532			
533			
534			
		for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany – for competent technical assistance.	535 536
	<b>Supplementary data</b>		537
	Supplementary data associated with this article can be found, in the online version, at <a href="http://dx.doi.org/10.1016/j.jhep.2015.11.018">http://dx.doi.org/10.1016/j.jhep.2015.11.018</a> .		538 539 540
	<b>References</b>		541
	<i>Author names in bold designate shared co-first authorship</i>		542
	[1] Drasdo D, Hoehme S, Hengstler JG. How predictive quantitative modelling of tissue organisation can inform liver disease pathogenesis. <i>J Hepatol</i> 2014;61:951–956.		543 544 545
	[2] Zellmer S, Schmidt-Heck W, Godoy P, Weng H, Meyer C, Lehmann T, et al. Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. <i>Hepatology</i> 2010;52:2127–2136.		546 547 548 549
	[3] Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. <i>Arch Toxicol</i> 2013;87:1315–1530.		550 551 552 553 554 555
	[4] Schliess F, Hoehme S, Henkel SG, Ghallab A, Driesch D, Bottger J, et al. Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. <i>Hepatology</i> 2014;60:2040–2051.		556 557 558 559 560
	[5] Hoehme S, Brulport M, Bauer A, Bedawy E, Schormann W, Hermes M, et al. Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. <i>Proc Natl Acad Sci U S A</i> 2010;107:10371–10376.		561 562 563 564 565 566 567
	[6] Campos G, Schmidt-Heck W, Ghallab A, Rochlitz K, Putter L, Medinas DB, et al. The transcription factor CHOP, a central component of the transcriptional regulatory network induced upon CCl4 intoxication in mouse liver, is not a critical mediator of hepatotoxicity. <i>Arch Toxicol</i> 2014;88:1267–1280.		568 569 570 571 572
	[7] Gebhardt R, Baldysiak-Figiel A, Krugel V, Ueberham E, Gaunitz F. Hepatocellular expression of glutamine synthetase: an indicator of morphogen actions as master regulators of zonation in adult liver. <i>Prog Histochem Cytochem</i> 2007;41:201–266.		573 574 575 576 577
	[8] Levesque R, Leblanc M, Cardinal J, Teitlebaum J, Skrobik Y, Lebrun M. Haemodialysis for severe hyperammonaemic coma complicating urinary diversions. <i>Nephrol Dial Transplant</i> 1999;14:458–461.		578 579 580 581 582
	[9] Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. <i>N Engl J Med</i> 2007;356:2282–2292.		583 584 585 586 587 588 589
	[10] Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. <i>Int J Hepatol</i> 2012;2012 480309.		590 591 592 593 594
	[11] Clay AS, Hainline BE. Hyperammonemia in the ICU. <i>Chest</i> 2007;132:1368–1378.		595 596 597 598 599
	[12] Rajpoot DK, Gargus JJ. Acute hemodialysis for hyperammonemia in small neonates. <i>Pediatr Nephrol</i> 2004;19:390–395.		
	[13] Summar M. Current strategies for the management of neonatal urea cycle disorders. <i>J Pediatrics</i> 2001;138:S30–S39.		
	[14] Honda S, Yamamoto K, Sekizuka M, Oshima Y, Nagai K, Hashimoto G, et al. Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy. <i>Biol Pharm Bull</i> 2002;25:1244–1246.		
	[15] Misel ML, Gish RG, Patton H, Mendlar M. Sodium benzoate for treatment of hepatic encephalopathy. <i>Gastroenterol Hepatol</i> 2013;9:219–227.		
	[16] Collen JF, Das NP, Koff JM, Neff RT, Abbott KC. Hemodialysis for hyperammonemia associated with ornithine transcarbamylase deficiency. <i>Appl Clin Genet</i> 2008;1:1–5.		
	[17] Boon L, Geerts WJ, Jonker A, Lamers WH, Van Noorden CJ. High protein diet induces pericentral glutamate dehydrogenase and ornithine aminotransferase to provide sufficient glutamate for pericentral detoxification of ammonia in rat liver lobules. <i>Histochem Cell Biol</i> 1999;111:445–452.		

## Research Article

- 599 [18] Sies H, Häussinger D, Grosskopf M. Mitochondrial nicotinamide nucleotide  
600 systems: ammonium chloride responses and associated metabolic transi-  
601 tions in hemoglobin-free perfused rat liver. *Hoppe Seylers Z Physiol Chem*  
602 1974;355:305–320.
- 603 [19] Spanaki C, Plaitakis A. The role of glutamate dehydrogenase in mammalian  
604 ammonia metabolism. *Neurotox Res* 2012;21:117–127.
- 605 [20] McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H. The  
606 mechanism underlying acetaminophen-induced hepatotoxicity in humans  
607 and mice involves mitochondrial damage and nuclear DNA fragmentation. *J*  
608 *Clin Invest* 2012;122:1574–1583.
- 609 [21] Meuret G, Beck K, Keul J, Gruenagel HH. On therapy of hepatic coma with  
610 metabolites of the urea cycle, glutamate and alpha-ketoglutarate. *Dtsch Med*  
611 *Wochenschr* 1968;93:1194–1197.
- 612 [22] Wildhirt E. The terminal stage of liver diseases and hepatic coma. *Der*  
613 *Internist* 1965;6:439–446.
- [23] Gebhardt R, Mecke D. Heterogeneous distribution of glutamine synthetase  
among rat liver parenchymal cells in situ and in primary culture. *EMBO J*  
1983;2:567–570.
- [24] Häussinger D. Hepatocyte heterogeneity in glutamine and ammonia  
metabolism and the role of an intercellular glutamine cycle during  
ureogenesis in perfused rat liver. *Eur J Biochem* 1983;133:269–275.
- [25] Stoll B, Häussinger D. Hepatocyte heterogeneity in uptake and metabolism  
of malate and related dicarboxylates in perfused rat liver. *Eur J Biochem*  
1991;195:121–129.
- [26] Stoll B, McNelly S, Buscher HP, Häussinger D. Functional hepatocyte  
heterogeneity in glutamate, aspartate and alpha-ketoglutarate uptake: a  
histoautoradiographical study. *Hepatology* 1991;13:247–253.

UNCORRECTED PROOF